Background: Breast cancer is the most common female malignancy and the leading cause of cancer mortality in women worldwide. The human epidermal growth factor receptor2 (HER2) is a transmembrane tyrosine kinase receptor that is usually overexpressed in human breast cancers. Stable cell lines heterogeneously overexpressing HER2 are highly required as in vitro models for breast cancer research. T...

More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings the PREDIX HER2 trial

Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for 15% of all cancers and this subtype was historically associated with poor outcomes. The development HER2-directed therapies has dramatically improved outcomes patients early advanced HER2+ disease. Trastuzumab is a HER2-targeted monoclonal antibody first approved the treatment in late 1990s. Since then, it been ...

The purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort 1981 dnMBC diagnosed between January 1995 and December 2017 at University Texas MD Anderson Cancer Center. OS measured from date diagnosis dnMBC. compared during different time periods: 5-year periods defined acc...

background: understanding of cellular and molecular mechanisms involved in cell/tumor growth and progression has led to molecular-targeted therapy. her1 and her2 are two main oncogenic components of her-receptor family considered as targets for cancer research and therapy. reliable results of her- related research and targeted therapies dependent upon cell line with known her expression status....

Evaluation of Receptor Conversion and HER2 Discordance between Primary Metastatic Breast Cancer Predictive factors

Background: Human epidermal growth factor receptor 2 (HER2) has a crucial role in several malignancies. The extracellular domain of HER2 (HER2-ECD) has been extensively employed as an important target in passive and active immunotherapy. Isolated recombinant prokaryotic HER2-ECD subdomains were previously found to be ineffective in inducing anti-tumor antibody response. Objective: To employ rec...

background: molecular biomarkers are valuable in evaluation the course of malignancies. in this study, the relationship be­tween her2/neu, p53, steroid receptors and clinicopathological features of patients with breast cancer has been assessed. methods : three hundred thirty nine women with a primary diagnosis of breast cancer from 2001 to 2006 were included. they were evaluated for tumor featu...

background: breast cancer is the most common cancer in women, containing approximately one third of all illnesses in women. assessment of molecular markers is valuable in predicting the outcome of disease and decision making for optimal treatment. the purpose of this study was to determine the relationship between estrogen and progesterone receptors with her-2, ki67, p53, and clinicopathologica...

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor family having tyrosine kinase activity. Overexpression of HER2 usually causes malignant transformation of cells and is responsible for the breast cancer. In this work, the virtual screening, molecular docking, quantum mechanics and molecular dynamics methods were employed to study protein–ligand ...